News

Resminostat, which is an oral pan-histone-deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II SHELTER study as a second-line treatment for advanced hepatocellular carcinoma as well as

The single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover study assesed the safety and pharmacokinetics of oral and IV administration of methamphetamine HCl in six healthy volunteers.

EPIAO is indicated as a treatment of chemotherapy-induced anemia. The Phase III active controlled, multi center and randomized trial evaluated the efficacy and safety of a weekly subcutaneous

CTP platform helps in extending the duration of activity of virtually all therapeutic proteins. The clinical and preclinical studies demonstrate that CTP technology is safe and effective in

USANA manufactures over 90% of its products in-house, including all of its tableted nutritional supplements. As an FDA-registered facility, USANA now has the ability to manufacture OTC drugs

With this acquisition, Hikma intends to strengthen its API sourcing and R&D capabilities in key product areas. The deal allows Hikma to get license to Haosun’s APIs particularly

Prime-A-Pump is a web-based knowledge resource and collaboration tool for building and maintaining smart-pump drug libraries. Zynx Health claims, Prime-A-Pump helps in improving the safety, quality and efficiency

The placebo controlled, randomized and single blind trial is intended to investigate the safety and efficacy o f ADXS-HPV in around three different dose cohorts. The company expects

Developed by using MonoSol Rx’s PharmFilm technology, Zuplenz is a film formulation that delivers either 4 or 8mgs of ondansetron. Zuplenz helps in preventing postoperative, highly and moderately